RISK FACTORS ASSOCIATED WITH EXACERBATION FREQUENCY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AT DISTRICT 11 HOSPITAL

Anh Tuấn Phạm, Thùy Trâm Phạm, Thanh Vũ Phạm, Kim Lụa Huỳnh, Diễm Hoài Phan, Chánh Xuân Trần, Thị Tuyết Lan Lê

Main Article Content

Abstract

Background/Objectives: COPD exacerbations increase burden on patients and healthcare systems, causing rapid lung function decline and increased mortality risk. This study aimed to describe clinical characteristics of COPD patients and analyze risk factors associated with exacerbation frequency. Methods: A cross-sectional descriptive study was conducted on 258 COPD patients at the Respiratory Clinic of District 11 Hospital from January 2022 to September 2024. Patients were divided into two groups: infrequent exacerbations (0-1 per year) and frequent exacerbations (≥2 per year). Logistic regression analysis identified risk factors associated with exacerbations. Results: Most patients were male (95.3%), Chinese ethnicity (61.2%), classified as GOLD 3 (72.5%) with mean FEV1 of 45.8%. The frequent exacerbation group had lower FEV₁ (41.6% vs. 51.3%, p<0.001), higher rates of current smoking (43.1% vs. 23.7%, p=0.004), and more comorbidities. The strongest risk factors were heart failure (OR=46.60), ischemic heart disease (OR=24.10), low FEV₁ (SMD=-1.42), and high CAT score (SMD=1.02). Conclusions: Cardiovascular comorbidities and poor lung function are the strongest risk factors for COPD exacerbations. Comprehensive assessment of COPD patients should emphasize screening and active treatment of cardiovascular comorbidities.

Article Details

References

1. Agustí, A., Celli, B. R., Criner, G. J., et al. (2023). Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. European Respiratory Journal, 61(4).
2. Chen, W., Thomas, J., Sadatsafavi, M., et al. (2015). Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. The Lancet Respiratory Medicine, 3(8), 631-639.
3. Hurst, J. R., Anzueto, A., Vestbo, J. (2017). Susceptibility to exacerbation in COPD. The Lancet Respiratory Medicine, 5(9), e29.
4. Lâm, H. T., Ekerljung, L., Tuong, N. V., et al. (2014). Prevalence of COPD by disease severity in men and women in northern Vietnam. COPD, 11(5), 575-581.
5. MacLeod, M., Papi, A., Contoli, M., et al. (2021). Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. Respirology, 26(6), 532-551.
6. Sin, D. D., Man, S. P. (2003). Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation, 107(11), 1514-1519.
7. Vanfleteren, L. E., Spruit, M. A., Groenen, M., et al. (2013). Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 187(7), 728-735.
8. Wedzicha, J. A., Seemungal, T. A. (2007). COPD exacerbations: defining their cause and prevention. The Lancet, 370(9589), 786-796.